Wellgistics Health (WGRX) announced significant Q2 operational results-adding 116 new pharmaceutical manufacturer partnerships, over 12,400 new products, and 275+ pharmacies to its national platform. “We’re in hyper structural transformation mode,” said Brian Norton, CEO of Wellgistics Health. “Pharma companies are signaling a shift. They want partners who can deliver speed, visibility, and direct access-not more layers of complexity. Every new manufacturer, every new product, and every new pharmacy is helping us rewire how prescriptions move in this country. We’re laying the foundation for real-time, patient-first drug access at national scale.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGRX:
- Wellgistics Health announces membership in OptiSource
- Wellgistics Health announces preliminary inclusion in Russell 2000, 3000 Indexes
- Wellgistics Health appoints Tony Madsen as COO, Shelley Bailey as CRO
- Wellgistics Health Updates Investor Presentation May 2025
- Wellgistics Health reports Q1 EPS (62c) vs. (0c) last year
